Goldman Sachs’s Biostage, Inc. Common Stock BSTG Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q4 | – | Sell |
-12,250
| Closed | -$4K | – | 6947 |
|
|
2017
Q3 | $4K | Buy |
12,250
+55
| +0.5% | +$22 | ﹤0.01% | 6593 |
|
|
2017
Q2 | $5K | Sell |
12,195
-461
| -4% | -$146 | ﹤0.01% | 6699 |
|
|
2017
Q1 | $5K | Sell |
12,656
-101
| -0.8% | -$55 | ﹤0.01% | 6665 |
|
|
2016
Q4 | $11K | Buy |
12,757
+404
| +3% | +$360 | ﹤0.01% | 6751 |
|
|
2016
Q3 | $13K | Sell |
12,353
-1,818
| -13% | -$1.96K | ﹤0.01% | 6845 |
|
|
2016
Q2 | $16K | Sell |
14,171
-526
| -4% | -$848 | ﹤0.01% | 6781 |
|
|
2016
Q1 | $26K | Buy |
14,697
+2,552
| +21% | +$4.23K | ﹤0.01% | 6676 |
|
|
2015
Q4 | $26K | Sell |
12,145
-218
| -2% | -$304 | ﹤0.01% | 6789 |
|
|
2015
Q3 | $10K | Sell |
12,363
-3,805
| -24% | -$4.31K | ﹤0.01% | 7148 |
|
|
2015
Q2 | $23K | Buy |
16,168
+3,951
| +32% | +$9.67K | ﹤0.01% | 7063 |
|
|
2015
Q1 | $40K | Sell |
12,217
-3,911
| -24% | -$13.3K | ﹤0.01% | 6763 |
|
|
2014
Q4 | $51K | Sell |
16,128
-3,434
| -18% | -$17K | ﹤0.01% | 6808 |
|
|
2014
Q3 | $158K | Sell |
19,562
-763
| -4% | -$6.24K | ﹤0.01% | 6344 |
|
|
2014
Q2 | $212K | Buy |
+20,325
| New | +$173K | ﹤0.01% | 6162 |
|
Goldman Sachs's BSTG Position: Q4 2017 in Review
Goldman Sachs sold out of Biostage, Inc. Common Stock (BSTG) in Q4 2017, closing a stake of 12,250 shares — an estimated $4K sold.
Goldman Sachs first reported a position in BSTG in Q2 2014 and held it in 14 quarters. The position peaked at $212K in Q2 2014. 0 funds tracked by Wall St. Rank hold BSTG as of Q4 2017.
- Goldman Sachs reported no remaining Biostage, Inc. Common Stock position as of Q4 2017 after selling out during the quarter.
- Goldman Sachs sold 12,250 Biostage, Inc. Common Stock shares in Q4 2017, an estimated $4K.
- Goldman Sachs first reported a position in Biostage, Inc. Common Stock in Q2 2014 and held it in 14 quarters.
- Goldman Sachs's Biostage, Inc. Common Stock position peaked at $212K in Q2 2014.
- 0 funds tracked by Wall St. Rank held Biostage, Inc. Common Stock as of Q4 2017.
Based on Goldman Sachs's 13F filing for Q4 2017, filed 14 Feb 2018.